Clinical trials
Long Term Adverse Effects trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
14 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2012 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 5 |
| Completed | 4 |
| Recruiting | 3 |
| Active, not recruiting | 1 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Auckland City Hospital | 1 |
| Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina | 1 |
| Ian Stewart | 1 |
| Intergroupe Francophone de Cancerologie Thoracique | 1 |
| Józef Piłsudski University of Physical Education | 1 |
| Karolinska University Hospital | 1 |
| Leiden University Medical Center | 1 |
| Marcela V. Maus, M.D.,Ph.D. | 1 |
| Mebo Research, Inc. | 1 |
| Peoples University, Bhanpur, Bhopal | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Long Term Adverse Effects | 14 |
| Anxiety Disorders | 1 |
| COVID-19 | 1 |
| Carcinoma, Non-Small-Cell Lung | 1 |
| Cerebral Small Vessel Diseases | 1 |
| Cognitive Dysfunction | 1 |
| Combat Disorders | 1 |
| Constipation | 1 |
| Critical Illness | 1 |
| Delirium | 1 |
Trials
Showing 1 to 14 of 14. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.